ProjectA randomised, double blind phase II trial to determine efficacy, safety and immunogenicity of BI 1361849 (CV9202)…
Basic data
Title:
A randomised, double blind phase II trial to determine efficacy, safety and immunogenicity of BI 1361849 (CV9202) maintenance vaccination therapy versus placebo given intradermally in newly diagnosed patients with inoperable locally advanced NSCLC after definitive concurrent chemoradiation therapy
Duration:
01/10/2015 to 30/09/2018
Abstract / short description:
A randomised, double blind phase II trial to determine efficacy, safety and immunogenicity of BI 1361849 (CV9202) maintenance vaccination therapy versus placebo given intradermally in newly diagnosed patients with inoperable locally advanced NSCLC after definitive concurrent chemoradiation therapy
Keywords:
clinical trial
klinische Studie
Involved staff
Managers
Faculty of Medicine
University of Tübingen
University of Tübingen
Cluster of Excellence: Image-Guided and Functionally Instructed Tumor Therapies (iFIT)
Centers or interfaculty scientific institutions
Centers or interfaculty scientific institutions
Contact persons
Department of Radiology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Local organizational units
Department of Diagnostic and Interventional Radiology
Department of Radiology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Funders
Ingelheim am Rhein, Rheinland-Pfalz, Germany